Your browser doesn't support javascript.
loading
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
Shi, Yuankai; Zhou, Jianying; Zhao, Yanqiu; Zhu, Bo; Zhang, Liangming; Li, Xingya; Fang, Jian; Shi, Jianhua; Zhuang, Zhixiang; Yang, Sheng; Wang, Donglin; Yu, Huiqing; Zhang, Longzhen; Zheng, Rongsheng; Greco, Michael; Wang, Tingting.
Afiliação
  • Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoy
  • Zhou J; Department of Respiratory Medicine, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Zhao Y; Department of Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhu B; Department of Oncology, Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
  • Zhang L; Department of Medical Oncology, Yantai Yuhuangding Hospital, Yantai, China.
  • Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Fang J; Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China.
  • Shi J; Department of Medical Oncology, Linyi Cancer Hospital, Linyi, China.
  • Zhuang Z; Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
  • Yang S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoy
  • Wang D; Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • Yu H; Department of Palliative Care, Department of Geriatric Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • Zhang L; Department of Radiotherapy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Zheng R; Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Greco M; Department of Drug Discovery, Beta Pharma Inc., Princeton, NJ, USA.
  • Wang T; Department of Clinical Development, Beta Pharma (Shanghai) Co., Ltd, Shanghai, China.
BMC Med ; 21(1): 11, 2023 01 08.
Article em En | MEDLINE | ID: mdl-36617560
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article